President Trump to lay out strategy for lowering drug prices

Before taking office, President Donald Trump railed against the pharmaceutical industry and accused it of “getting away with murder.”

Posted: May 11, 2018 1:38 PM

WASHINGTON (AP) — Before taking office, President Donald Trump railed against the pharmaceutical industry and accused it of “getting away with murder.”

The populist rhetoric appears to be giving way to a more nuanced strategy focused on making the pharmaceutical market more open and competitive, with the aim of lowering costs for consumers.

It’s an approach that could avoid a direct confrontation with the powerful pharmaceutical lobby, but it could also underwhelm Americans seeking relief from escalating prescription costs.

On Friday, Trump is scheduled to give his first speech on an overarching plan to lower drug prices. Administration officials previewing the speech Thursday touted it as the most comprehensive plan to tackle prescription drug costs that any president has ever proposed, but offered few specifics.

Officials said the plan would increase competition, create incentives for drugmakers to lower initial prices and slash federal rules that make it harder for private insurers to negotiate lower prices. The result would be lower pharmacy costs for patients — a key Trump campaign promise.

The plan will not include giving the federal Medicare program power to directly negotiate prices with drugmakers, they noted. Trump campaigned on the idea, which is vigorously opposed by the pharmaceutical industry.

Public outrage over drug costs has been growing for years, because Americans are being squeezed in a number of ways: New medicines for cancer and other life-threatening diseases often launch with prices exceeding $100,000 per year. Drugs for common ailments like diabetes and asthma routinely see price hikes around 10 percent annually. Meanwhile some companies have been buying up once-cheap older drugs and hiking prices by 1,000 percent or more.

Since entering the White House, Trump has backed away from reforms directly targeting drugmakers and staffed his administration with appointees who have deep ties to the industry, including his health secretary, Alex Azar, a former top executive at Eli Lilly.

Still, administration officials ratcheted up the rhetoric ahead of Trump’s speech. Azar promised bold action. FDA Commissioner Scott Gottlieb — another Trump appointee with industry connections — hinted at a plan to “dismantle” the convoluted system of discounts and rebates between drugmakers and health care middlemen.

On Thursday, administration officials also vowed to address foreign governments that rely on U.S. medicines but pay drastically lower prices due to government controls. The U.S. accounts for 70 percent of the world’s brand-name drug profits, according to a White House report released earlier this year.

Here are some of the drivers of U.S. prescription drug prices, proposals for reducing the costs and what’s at stake:

LACK OF REGULATION

Drugmakers generally can charge as much as the market will bear because the U.S. government doesn’t regulate medicine prices, unlike most other countries.

Medicare is the largest purchaser of prescription drugs in the nation, covering 60 million seniors and Americans with disabilities, but it is barred by law from directly negotiating lower prices with drugmakers. Democrats have long favored giving Medicare that power, but Republicans traditionally oppose the idea.

The powerful pharmaceutical lobby has repeatedly fended off proposals that could lower prices, such as Medicare negotiations or importing drugs from countries that regulate pricing.

With no direct government price regulation, the primary check on prices comes from buyers in bulk — such as insurance companies and pharmacy benefit managers, which handle prescription coverage for insurers, employers and other big clients.

But because there are so many players in the fragmented system, the discounts achieved in the U.S. are generally far more modest than those in other countries.

The result is that the U.S. spends more on medicines than any other nation. In 2015, the U.S. spent $1,162 per person on pharmaceuticals, according to the Organization for Economic Cooperation and Development. That compares with $756 for Canada and $497 for the United Kingdom, both of which have government measures to control drug prices.

LACK OF TRANSPARENCY

The U.S. system for pricing drugs is notoriously complex, so much that the “real” price for most medicines isn’t clear. Critics contend that this lack of transparency limits competition and drives prices higher.

Pharmaceutical companies often launch their drugs with high initial prices. But they argue list prices are merely a starting point for negotiations because they give substantial rebates and discounts to pharmacy benefit managers. Those price concessions are almost never disclosed and it’s unclear what portion actually flows back to consumers.

FDA Commissioner Scott Gottlieb and others say the lack of transparency in the current system creates perverse incentives in which drugmakers and other health care companies benefit from rising prices — at the expense of patients.

Trump officials have suggested requiring Medicare pharmacy benefit managers to share rebate payments with patients. Another proposal would do away with rebates altogether to encourage more upfront discounts in Medicare.

But the benefit managers and insurers say that they use rebates to lower health care premiums overall and that doing away with them would drive up costs.

PATENTS AND ANTI-COMPETITIVE TACTICS

Patents last longer in the U.S. than most countries, typically giving companies a dozen years of competition-free marketing after a drug launches. Most drugmakers increase their prices annually during this monopoly period, and until recently double-digit price hikes were the norm.

Drugmakers also have developed a number of techniques to block competitors from launching lower-cost generic drugs. Companies often tweak drug formulations to extend their patents. In other cases, companies directly pay would-be competitors to stay off the market in so-called “pay-to-delay” deals.

Gottlieb has promised a crackdown on some of these techniques used to “game the system.” He’s highlighted a practice in which drugmakers use tightly controlled distribution systems to prevent rival manufacturers from purchasing their drug. This effectively blocks the development of generic versions because generic drugmakers must test their products against the original medicine before they can win FDA approval.

PUBLIC PERCEPTION

A majority of Americans say bringing down prescription drug prices should be a “top priority” for Trump and Congress, according to recent polling by the Kaiser Family Foundation.

And experts who study drug pricing say it’s encouraging that the discussion around the issue has moved from outrage to sophisticated reforms. But some warn there is no guarantee that unraveling the current pricing-setting bureaucracy will lead to lower prices, because it all starts with drugmakers’ prices.

“Until we get closer to policy solutions that address the ability of drug manufacturers to set whatever price they want and increase prices year after year we may only be scratching the surface of this problem,” said Juliette Cubanski, a health care expert with the nonpartisan Kaiser Family Foundation.

Dan Mendelson, a health care consultant, said: “If they don’t address the cost that patients see at the pharmacy counter it’s not going to be seen as responsive.”

Terre Haute
Partly Cloudy
57° wxIcon
Hi: 57° Lo: 40°
Feels Like: 57°
Robinson
Clear
57° wxIcon
Hi: 59° Lo: 42°
Feels Like: 57°
Indianapolis/Eagle Creek
Partly Cloudy
52° wxIcon
Hi: 55° Lo: 37°
Feels Like: 52°
Paris
Partly Cloudy
52° wxIcon
Hi: 55° Lo: 40°
Feels Like: 52°
Mattoon/Charleston
Partly Cloudy
52° wxIcon
Hi: 56° Lo: 41°
Feels Like: 52°
Terre Haute
Partly Cloudy
57° wxIcon
Hi: 58° Lo: 40°
Feels Like: 57°
Terre Haute
Clear
57° wxIcon
Hi: 57° Lo: 39°
Feels Like: 57°
Partly sunny, warm.
WTHI Planner
WTHI Temps
WTHI Radar

Latest Video

Image

All You Need to Know for Wednesday

Image

Paycheck Protection program help and changes

Image

One city in the Wabash Valley is receiving $2.6 million in federal funding

Image

Wednesday: Partly sunny, warm. High: 55

Image

Casey-Westfield Marshall

Image

West Vigo Cloverdale

Image

Northview Edgewood

Image

TH South Linton

Image

Linton trio

Image

Loogootee seniors

WTHI Events

 

Illinois Coronavirus Cases

(Widget updates once daily at 7 p.m. CT)

Cases: 1177241

Reported Deaths: 22528
CountyCasesDeaths
Cook4709339291
DuPage761561188
Will64432882
Lake58864915
Kane50242708
Winnebago28194431
Madison27715451
St. Clair25173463
McHenry24076261
Champaign17908123
Peoria16772260
Sangamon16028216
McLean14485156
Tazewell13397239
Rock Island12991285
Kankakee12383188
Kendall1093783
LaSalle10681216
Macon9386185
Vermilion8487114
DeKalb8165111
Adams7970113
Williamson6763119
Boone590471
Whiteside5881146
Clinton555189
Coles515990
Grundy506762
Knox5010131
Ogle497373
Jackson458560
Effingham448169
Macoupin432178
Henry430456
Marion4253111
Livingston414475
Franklin412665
Stephenson406273
Monroe403280
Jefferson3953115
Randolph395177
Woodford363360
Morgan356776
Montgomery346067
Lee332443
Logan329952
Christian328565
Bureau327373
Fayette306152
Perry302357
Fulton283044
Iroquois276560
Jersey247945
Douglas241032
McDonough230440
Lawrence228524
Saline227046
Union218134
Shelby211834
Crawford200021
Bond189124
Cass187522
Pike168249
Clark167329
Hancock166529
Warren166243
Wayne166248
Richland163238
Jo Daviess159822
White159525
Washington157223
Carroll156434
Ford156344
Edgar153737
Moultrie148622
Clay142241
Greene137631
Johnson133911
Piatt130714
Wabash129612
Mercer127532
De Witt127322
Mason127141
Massac124932
Cumberland118318
Jasper110217
Menard10318
Marshall83114
Hamilton78315
Schuyler6745
Pulaski6675
Brown6586
Stark53522
Edwards52210
Henderson4958
Calhoun4752
Scott4481
Alexander4428
Gallatin4354
Putnam4093
Hardin34412
Pope2803
Out of IL00
Unassigned02198

Indiana Coronavirus Cases

(Widget updates once daily at 8 p.m. ET)

Cases: 657037

Reported Deaths: 12450
CountyCasesDeaths
Marion901321624
Lake48105871
Allen35552632
Hamilton31839393
St. Joseph29538510
Elkhart25261412
Vanderburgh21115377
Tippecanoe19765197
Johnson16242352
Porter15838267
Hendricks15723296
Clark11843179
Madison11672314
Vigo11503228
Monroe10248158
Delaware9788178
LaPorte9720194
Howard9017194
Kosciusko8514107
Bartholomew7373147
Warrick7369146
Hancock7362128
Floyd7139164
Wayne6586188
Grant6395157
Morgan6040124
Boone603388
Dubois5868111
Dearborn540266
Henry539492
Marshall5390104
Cass537199
Noble506775
Jackson462063
Shelby458490
Lawrence4154111
Gibson399681
Harrison395160
Clinton392353
DeKalb382078
Montgomery381583
Knox354484
Miami354063
Whitley346235
Huntington338176
Steuben335955
Wabash328775
Putnam325959
Ripley325161
Adams320249
Jasper312943
White295351
Jefferson292770
Daviess284296
Fayette270255
Decatur269388
Greene259978
Posey259731
Wells255374
Scott248446
LaGrange240170
Clay238944
Randolph225076
Spencer215830
Jennings213544
Washington207727
Sullivan202038
Fountain200341
Starke185950
Owen181652
Jay177328
Fulton176437
Carroll175618
Perry172435
Orange170450
Rush163922
Franklin158335
Vermillion158040
Tipton145441
Parke137915
Pike127232
Blackford120027
Pulaski105643
Newton96431
Brown94639
Benton91113
Crawford90113
Martin80114
Switzerland7507
Warren74612
Union66810
Ohio52711
Unassigned0425